Thank you, Victor. It's my pleasure to welcome everyone to today's conference call to discuss our full year financial results for 2020 and to provide a business update.

Before we begin, I'd like to remind everyone that today's call will contain forward-looking statements based on current expectations. Such statements may involve risks and uncertainties that may cause actual results to differ materially from these stated expectations.

For further information on the company's risk factors, please see Liquidia's filings with the Securities and Exchange Commission at www.sec.gov or on Liquidia's website at www.liquidia.com. I would now like to turn the call over to our Chief Executive Officer, Damian deGoa for our prepared remarks, after which he'll open the call for your questions.

Thank you, Jason, and good morning, everyone. We hope you and your families remain healthy.

I'm excited to speak with you today on my first earnings call for Liquidia. I began with Liquidia mid-December.

As you might expect the last three months have been busy as we position Liquidia for the future. But before we jump into the full corporate update and review of 2020 financials, I would like to take a moment to introduce a few of the new members of the management team.

Joining me on the call today are Mike Kaseta, our Chief Financial Officer who joined in November; Scott Moomaw, our Senior Vice President of Commercial who joined as part of the RareGen merger also in November; and Dr. Thushar Shah, our Chief Medical Officer and Head of R&D who joined in May.

The rest of the Management team includes Rob Lippe, our Chief Operations Officer, who has helped scale print [ph] technology over the last six years; Jason Adair, who you've met and continues to lead Business Development and Investor Relations. And lastly, I'm pleased to announce that effective next week, Rusty Schundler will join Liquidia as Senior Vice President and General Counsel.

Rusty has served as General Counsel at PBM Capital Group where he and I worked together for more than five years. What can you expect from our leadership team?

We will operate with a sense of urgency; we will be decisive and results-oriented; we will be financially-disciplined and efficient; we will focus on value-creating objectives; we will be entrepreneurial and approach growth as an investor and manager. As the newly assembled management team, our initial thoughts on the company are as follows.

LIQ861, our inhaled dry powder formulation of treprostinil is a great product with very good market potential. The patient benefits are clear.

We recognize that we have work to do to achieve final approval, including: one, responding to the complete response letter issued by the FDA last November; two, preparing for a prior approval inspection by the FDA; and three, achieving a successful outcome in its Hatch-Waxman Litigation brought by United Therapeutics. We know what we have to do and are executing on those plans.

We also have an attractive commercial product, treprostinil injection that we promote in partnership with Sandoz. This AP-rated generic formulation of Remodulin offers the same active and inactive ingredients with the same patient and physician services without the lower costs of the healthcare system.

The perennial delivery of treprostinil remains a sizable market and we see opportunity to increase utilization of our product. We have a unique innovative platform in print technology.

There's clear advantage in inhaled therapies, but also applications that have been explored in vaccines, antiviral, implants, topicals and biologics. We're actively considering new internal R&D product candidates that can either leverage our expertise in pulmonary hypertension or the value of prints.

We will discuss more about the R&D pipeline as things evolve. We have an asset and 865 to control post-operative pain that we feel is best positioned with a strategic partner which I will address in a few minutes and we need to look for value creating opportunities both from our R&D and business development.

This team will strive to provide balance and transparent insights in the actions and decisions of the company. For the time being, Liquidia is a small company and the impact of many events are magnified.

We understand these details can be important to investors but need to be managed with due sensitivity, such as around active litigation, competitive intel related to treprostinil injection, and details of regulatory interactions. So with the future in mind, I'd like to summarize some of the key activities from 2020 and the recent past.

First, we have evolved the company from a clinical stage to one with commercial presence in PAH. Having closed the RareGen merger transaction in November, there have been no interruptions to commercial support of Sandoz' first to file generic treprostinil injection.

Despite the current limitation to IV administration only, demand for treprostinil injection remains consistent and strong even as new generics have entered and commercial activities have been limited due to COVID. We continue to see increasing potential for generic utilization as parents consider adoption and physicians become more familiar.

And importantly, we now have a PAH-focused salesforce that establishes the initial commercial infrastructure needed to launch 861. Prior to restructuring at Liquidia corporation, much of our activity last year was tied to the FDA review of 861.

In January, the company submitted an NDA for the first product enabled by our proprietary print technology and the first dry powder inhaled treprostinil. Though we were disappointed to receive a CRL, we remain confident in our ability to address the items sufficiently and bring 861 to the market as soon as possible.

To that end, we expect to submit our formal response to CRL in the middle of the year. This project time line has been informed by our Type A meeting with the FDA in January.

As previously announced, the items that lead to the CRL were related to the need for additional information and clarification of CMC data and device biocompatibility. The CRL did not require any additional studies in areas of toxicology, pharmacology or clinical exposure to patients.

We're fully prepared to host the FDA for an on-site inspection at Liquidia and our manufacturing partners after our response has been submitted. While the 861 team works on the CRL response, the new management team has extended our cash runway by making financially-disciplined choices to operate until 861 can be approved.

Specifically, over the last few months, we have implemented changes that will reduce our net cash expenses in 2021 by more than 40% when compared to spending in 2020. Mike will outline some of the components of those savings.

As a result of these quick decisions, the company is well-positioned to drive value through key events in 2021 and 2022 beyond the projected expiration of the regulatory state in October 2022. To that point, we continue to progress the Hatch-Waxman Litigation brought by United Therapeutics and our concurrent IPR efforts at the US Patent Office.

We believe the patents being asserted are not infringed nor valid. We are confident in our arguments to be made in court, but will not be commenting in detail on these ongoing proceedings.

Anticipating commercial success, Liquidia has strengthened its intellectual property and competitive position with the issuance of the 494 patent which expires in 2037. Enabled by the print formulation and clinical evidence of 861, the claims to this patent were first allowed last August and relate to methods of treating pulmonary hypertension -- not just pulmonary arterial hypertension.

With doses between approximately 100 micrograms to approximately 300 micrograms of dry powder treprostinil. Specifically, more than 75% of patients enrolled in our pivotal and extension studies have received 861 doses of 100 micrograms or more.

We believe those dose levels may be translating to a patient benefit over time, having treated more than 75 patients for longer than two years. With regard to 865 as stated in earlier filing, we're advanced in conversations with external collaborators about continued development.

To ensure we achieve our near term financial objectives as well as provide 865 with the highest chances of success, we feel it is important to collaborate with partners already working in the field of pain management. We look forward to working to updating you on these efforts in the future call, though to be clear, investment in 865 has been paused until these business discussions conclude.

At this time, I'll turn the call over to Mike to review our full year financial summaries.

Thank you, Damian, and good morning, everyone. Our full-year 2020 financial results can be found in the press release issued earlier today and on our Form 10-K to be filed with the SEC in the coming days, both of which will be available on our website.

In those documents, you will see that revenue was $0.7 million for the full-year of 2020, compared with $8.1 million for the full-year of 2019. The decrease is due to the full recognition in the second quarter of 2019 of $8.1 million of deferred revenue from the company's agreement with GSK for which there was no comparable revenue in 2020.

Revenue related to sales in treprostinil injection was recognized for the period from closing of the merger transaction, November 18 to year end. Research and development expenses were $32.2 million for the full-year of 2020 compared with $40.5 million for the full-year of 2019.

The decrease primarily related to lower expenses for the company's 861 clinical program, which was substantially completed prior to filing of the NDA in April 2020 and lower expenses from the company's 865 clinical program. General administrative expenses were $27.4 million for the full-year of 2020, compared with $13.6 million for the full-year of 2019.

This increase was due to $4.8 million in expenses related to the merger transaction, $2.4 million in legal and patent expenses from the company's ongoing 861-related litigation, an increase of $5.8 million in outside consulting expenses and personnel costs, including surveys comp, and a one-time charge of $1.4 million associated with the reduction of headcount. In summary, we have incurred a net loss of $59.8 million for the full year 2020 or $1.76 per basic and diluted share, compared to a net loss of $47.6 million, or $2.57 per basic and diluted share for the full-year of 2019.

Let me now shift and discuss our cash on hand and the actions taken to provide stable financial footing in 2021 and beyond. As of December 31, we had $65.3 million of cash on our balance sheet.

As Damian mentioned earlier, our operating plan this year should result in more than a 40% reduction in net annual spending compared to spending in 2020. This reduction is more than twice the anticipated savings projected on the third quarter earnings call.

Some of the changes implemented since Damien and I joined the company include refinancing the existing credit facility with a new facility providing interest only payments for the first 24 months, which saves more than $10 million over the next few years; reducing internal staff and full time equivalent of consultants by nearly 40%; refinancing equipment leases; and finding other opportunities for increased efficiency across operation. This improvement in cash expenditures will be further amplified by the anticipated positive contribution from the profit split arrangement with Sandoz on the sale of treprostinil injection.

As this product is registered under Sandoz, we will not be providing any specific revenue guidance. However, we are confident that the intravenous use of the treprostinil injection will contribute revenue to Liquidia in the mid to high single digit millions as discussed at the time of the merger transaction.

We will provide updates on future calls, should this change in any material way. I'm encouraged to say that the combination of cash saving measures plus positive contract revenue should extend our cash runway to the value creating events related to the regulatory approval and litigation activity in 2021 and 2022.

I'd now like to turn the call back over to Damian.

Thank you, Mike. Having reflected on the major activities of the company in 2020 and my first three months on the job, I'd like to make a couple of points for you before taking your questions.

First, we are committed to 861 and doing everything we can to achieve FDA approval. It's a great product with tremendous market potential.

Second, we will exercise financial discipline and look for value-creating opportunities in R&D and business development as we look to build value in the near and midterm. I will now turn the call over to the operator to take your question.

Excellent. Thank you.

Good morning, everybody and thanks for taking the questions. I guess the first one for me would be just kind of if we can have any more color in terms of what the operational activities would be required to kind of satisfy the deficiencies with respect to the biocompatibility information?

I guess I'm just trying to find out what technically or tactically you have to do to kind of accomplish those goals. And then the second question for me would be just kind of remind us in terms of where we're at in terms of the ongoing litigation from a just procedural perspective and what news flow we might be able to expect out of that process over the coming months?

Thanks.

Hey, Chris. Thanks.

I think in terms of the biocompatibility, we've basically taken that over from our partner, plus the update [ph] and we are we are basically doing a full biocompatibility testing. That's all underway and ongoing as we speak.

Those results are part of the time line in things that we need to resolve prior to being able to respond to the CRL response. However, this device has been used in millions of patients and been on the market for a number of years and in prior versions.

So we feel pretty confident in it, but we just need to do the work. In relation to the ongoing litigation, I would say the next major event is the claims construction that will occur in May of 2021.

And, Chris, we're probably going to take a little bit more of a higher level response on kind of the activities on a day-to-day basis, if you will, of the ongoing litigations and we'll probably let our litigators do what they do and then provide comment as appropriate.

Sure, yes. Totally understood.

So basically, the Markman hearing should be coming up and that's the next potentially public viewing in terms of new information. Is that kind of the correct perspective?

That's right.

Okay. Aright.

Well, thanks again for taking the questions and look forward to the continued progress.

Thanks, Chris.

Good morning and thank you for all the updates on the quarter. It's Andreas, on for Liana Moussatos.

I'm going to keep it brief myself. Regarding 865, you're hoping strategic partnership development until you find a strategic partner.

What might a partnership look like? What are you expecting?

Any color on that? Thanks.

Yes, I think it's too early to say Andreas. I think that we do have several interested parties.

And I think there's a lot of factors that will go into who's the right potential partner. In terms of terms or financials related to that, it's too early to have any discussions around that.

Okay. And then just one on the patent litigation.

In the press release, you mentioned this October coming up as another potential event. How might a favorable decision by the PTAB to institute the IPR for 793 shift time lines and potential approval and launch?

Thanks.

Thanks. Good question.

I don't think it will actually have any impact on the overall timing. The October would be when the PTAB would decide whether or not to accept the petition.

And then it would be 12 months resolved thereafter. So that that coincides pretty consistently with the Hatch-Waxman Litigation resolution in October of 2022.

Okay, thanks for the clarity, guys. Look forward to catching up later and congrats again on the quarter.

Hi. Good morning.

Couple of questions for me. First one on the generic Remodulin product.

Can you just talk about your outlook for that product for 2021? And then secondly, I think when the CRL was issued last fall, the pre-approval inspection and not being completed, have you gotten any color on that or that's going to be contingent on resubmitting the NDA for that to be scheduled?

Thank you.

Thanks, Serge. In relation to generic Remodulin, the treprostinil injection product, we feel pretty good about that.

As I kind of mentioned, it's the same product, it's AP-rated, it's same active, same inactives. We've done a lot to make sure that we provide the exact same services that the patients and the physicians have come to expect, and we do it all with a lower cost.

I think all those positives should lead to continued utilization of our products. We are in a COVID environment and right now the delivery is through intravenous, which means that patients would be getting a central line.

And so that certainly is a consideration for physicians as they start new patients as to whether or not they're going to bring patients in for that procedure. So there is certainly some headwinds from COVID, but this is a life-sustaining drug, so patients are going to continue to be on it even during this COVID pandemic.

So, we feel good about the product. I think we're doing it in a smart way in terms of the way that we're approaching it, not just as a generic, but kind of with this branded approach to promoting the brand or the generic.

And so we expect positive things there. From the prior approval inspection perspective, that was not conducted, but we fully expect that the FDA will be doing an inspection.

We don't know when or what the timing would be, but we would expect it to be sometime after we respond to the CRL.

Great. Well, thanks, everyone, for joining us today and we appreciate your continued interest and investment in Liquidia.

And we look forward to providing more progress throughout the year. Have a great day.